Skip to main content

Table 1 Volume market share and annual therapy cost per patient of new antidiabetic medicines, all insulins, and old antidiabetic medicines in 2016

From: Uptake of new antidiabetic medicines in 11 European countries

Country Volume market share in 2016 Annual therapy cost in 2016
New antidiabetic medicinesa (%) All insulins
(%)
Old antidiabetic medicines (%) New antidiabetic medicinesa (€) All insulins (€) Old antidiabetic medicines (€)
Austria 26.1 (20.8)b 24.1 49.8 460 326 55.8
Croatia 10.8 (8.7)b 20.8 68.4 371 270 36.9
France 17.7 (14.6)b 21.1 61.3 480 386 56.6
Germany 22.9 (17.5)b 36.2 40.9 513 500 32.1
Hungary 10.3 (7.5)b 26.5 63.2 474 239 45.1
Italy 8.8 (6.3)b 21.5 69.7 499 326 43.3
Poland 1.5 (1.1)b 23.5 75.0 363 173 26.9
Slovenia 6.6 (4.1)b 29.0 63.5 427 284 58.0
Spain 26.3 (21.2)b 23.4 50.3 456 328 25.7
Sweden 9.7 (5.8)b 35.2 55.1 769 373 15.9
UK 10.6 (6.8)b 22.2 67.2 668 390 56.2
  1. Legend: aDPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
  2. bValues in brackets indicate the volume market share for DPP-4 inhibitors